Acurx Pharmaceuticals Successfully Closes Registered Direct Offering
Staten Island, NY, March 10, 2025 – Acurx Pharmaceuticals, Inc., a pioneering biopharmaceutical company specializing in the development of innovative antibiotics for challenging bacterial infections, announced the successful completion of its registered direct offering. This offering included the sale of 2,745,000 shares of Acurx’s common stock, or common stock equivalents, at a purchase price of $0.40 per share (or per common stock equivalent).
Impact on Acurx Pharmaceuticals
This offering represents a significant milestone for Acurx as it brings in additional capital to support the continued advancement of its lead product candidate, Dificid, which is being developed for the treatment of Clostridioides difficile (C. diff) infections. The funds will also be used to progress the clinical development of its second product candidate, Oritavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
With the successful closing of this offering, Acurx now has a strengthened financial position, enabling it to execute on its strategic plans more effectively. This includes continuing clinical trials, preparing for regulatory submissions, and building partnerships to expand its reach in the market.
Global Impact
The closing of Acurx’s registered direct offering is a positive sign for the biopharmaceutical industry, particularly in the area of antibiotic development. The ongoing threat of antibiotic-resistant bacteria necessitates the development of new, effective treatments. Acurx’s focus on creating a new class of antibiotics addresses this critical need.
Moreover, the successful fundraising round demonstrates investor confidence in Acurx’s innovative approach and potential to make a significant impact on global health. As Acurx continues to advance its pipeline, it could lead to new treatments for difficult-to-treat bacterial infections, benefiting patients worldwide.
Conclusion
In summary, Acurx Pharmaceuticals’ successful closing of its registered direct offering marks an essential step forward in the company’s mission to develop innovative antibiotics for challenging bacterial infections. The funds raised will support the continued progress of Dificid and Oritavancin, bringing potential new treatments to patients while addressing the growing threat of antibiotic resistance. This achievement not only benefits Acurx but also the global community, as it brings us one step closer to overcoming the challenges posed by antibiotic-resistant bacteria.
- Acurx Pharmaceuticals successfully closes registered direct offering
- 2,745,000 shares of common stock sold at $0.40 per share
- Proceeds to be used for clinical trials, regulatory submissions, and partnerships
- Positive sign for the biopharmaceutical industry and investor confidence
- Addresses the critical need for new, effective antibiotics to combat antibiotic-resistant bacteria
